TEL AVIV, Israel--(BUSINESS WIRE)--BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reported the establishment of a Scientific Advisory Board (SAB) to provide insight and guidance on the Company’s activities in the field of oncology.
